TIDMMED

RNS Number : 2813J

Medaphor Group PLC

08 September 2016

MedaPhor Group plc

("MedaPhor" or the "Group" or the "Company")

Notice of material contract change

MedaPhor Group plc (AIM: MED), the global provider of advanced ultrasound skills training simulators for medical professionals, announces that the American Board of Obstetrics and Gynecology (ABOG) has served notice on the Company to terminate its contract with MedaPhor.

The directors believe that MedaPhor's business relationship with ABOG is a good one and can be resurrected.

The ABOG has apprised MedaPhor that, if the patent infringement action which was announced by the Company on 27 April 2016 is resolved in a manner that is satisfactory to the ABOG, and there are no other threats to MedaPhor's ability to market, sell and support its ScanTrainer and related technology, the ABOG would certainly welcome the opportunity to again do business with MedaPhor. The ABOG also indicated that nothing it has done or indicated should be construed as (i) any modification to the Notice of Termination which it has communicated to MedaPhor or (ii) any agreement to modify the Notice of Termination.

As stated previously, the directors believe that the patent infringement action is without merit and the Company is currently challenging the plaintiff's standing to bring the action, vigorously defending its non-infringement position, as well as preparing to challenge in court the validity of the patent in question. The priority for the Group clearly remains to prevail on this patent infringement action and resurrect the ABOG relationship. The Company will update the market on progress made in this regard as appropriate

Enquiries:

 
 MedaPhor Group plc                     www.medaphor.com 
 Stuart Gall, CEO               Tel: +44 (0)29 2075 6534 
 
 Cenkos Securities              Tel: +44 (0)20 7397 8900 
 Bobbie Hilliam (Nominated 
  Adviser) 
 Julian Morse (Corporate 
  Broking) 
 
 Walbrook PR                 Tel: +44 (0)20 7933 8780 or 
                                 medaphor@walbrookpr.com 
 Paul McManus / Anna          Mob: +44 (0)7980 541 893 / 
  Dunphy                        Mob: +44 (0)7876 741 001

This announcement contains inside information

About MedaPhor (www.medaphor.com)

MedaPhor (AIM: MED) is a global provider of advanced ultrasound skills training simulators for medical professionals. Founded in 2004, the Company is headquartered in Cardiff, UK and San Diego, USA, with customers in over 16 countries across the world.

Following its recent acquisition of Inventive Medical, the company now has two of the world's leading ultrasound training simulators:

ScanTrainer Professional, MedaPhor's market-leading ultrasound skills training simulator, offers a realistic ultrasound scanning learning experience that combines 'real-feel' haptic technology with real full anatomy patient scans, real-time one-to-one expert guidance and curriculum based teaching. The system offers trainees a flexible self-learning experience without the need for patients and with minimal requirement for expert supervision - making ScanTrainer Professional both resource efficient and highly cost effective.

ScanTrainer Professional's subscription-based Cloud 2 service offers ScanTrainer users access to the unique Case Generation Engine, which enables clinicians to upload and publish their own patient scans and share these with other Cloud 2 subscribers within their organisation or around the world. In addition, ScanTrainer's Cloud Case Library offers users flexible cloud-access to a growing library of nearly 300 normal and abnormal cases created using real patient scans.

HeartWorks, developed by leading cardiac anesthesiologists at University College London Hospitals, the HeartWorks simulators and online training materials are recognised as one of the most true-to-life and comprehensive educational tools for Transthoracic and Transoesophageal echocardiography.

Medical practitioners can learn, through interactive online content, the complete anatomy of the heart, view it from all angles and recognise patient cases with pathological conditions. They can then practise acquiring ultrasound images though correct probe positioning on a simulator, interpret those images to determine correct diagnosis and treatment, and finally be tested to ensure that all required competencies have been achieved to the highest standard.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCAKFDPPBKKDCK

(END) Dow Jones Newswires

September 08, 2016 02:01 ET (06:01 GMT)

Intelligent Ultrasound (LSE:IUG)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Intelligent Ultrasound Charts.
Intelligent Ultrasound (LSE:IUG)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Intelligent Ultrasound Charts.